Perspectives on the development of a molecularly targeted agent
Open Access
- 1 February 2002
- journal article
- review article
- Published by Elsevier in Cancer Cell
- Vol. 1 (1) , 31-36
- https://doi.org/10.1016/s1535-6108(02)00025-9
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Sceptical scientistsThe Lancet, 2001
- Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia ChromosomeNew England Journal of Medicine, 2001
- Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid LeukemiaNew England Journal of Medicine, 2001
- The molecular biology of chronic myeloid leukemiaBlood, 2000
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature, 2000
- Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemiaJournal of Clinical Investigation, 2000
- CGP 57148, a Tyrosine Kinase Inhibitor, Inhibits the Growth of Cells Expressing BCR-ABL, TEL-ABL, and TEL-PDGFR Fusion ProteinsBlood, 1997
- Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cellsNature Medicine, 1996
- Induction of Chronic Myelogenous Leukemia in Mice by the P210
bcr/abl
Gene of the Philadelphia ChromosomeScience, 1990
- A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemiaNature, 1982